In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cell Therapeutics Europe SRL

Division of CTI BioPharma Corp.
www.cticseattle.com

Latest From Cell Therapeutics Europe SRL

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2008

Highlights from the Q1 2008 review of pharmaceutical and biotechnology dealmaking: there was a drought in biopharma financings--particularly from the public markets with only two completed IPOs--but VC funding was strong and made up 40% of the total. M&A activity was also down and saw only one multi-billion dollar deal. In alliances, oligonucleotides were the subject of seven biopharmaceutical collaborations and accounted for most of the quarter's dealmaking money.
BioPharmaceutical

VCs Eye Europe's Drug Cabinet: Index, Orion Share Designs on Clinical Stage Compounds

Two new investment vehicles have been formed to take advantage of the relative immaturity of Europe's life sciences industry. Index Ventures and Orion Health Care Equity Partners both see opportunities abound in Europe's biopharmaceutical start-ups, but they have different approaches.
BioPharmaceutical Europe

Sofinnova's Window on Early-Stage Technology in Europe

In Europe, one of the historical obstacles to company creation has been a lack of venture capital funding. Not any longer. Abingworth's life-science-focused fund, Abingworth Bioventures IV, raised $350 million; Schroder Ventures Life Sciences' fund International Life Sciences III was $402 million; and the latest life sciences fund of Techno Venture Management was $450 million. These funds now rival their counterparts on the East Coast or the Bay area of the US. Now, the Paris-based venture capital firm Sofinnova Partners has closed its fifth fund, at €385 million ($516 million). Sofinnova Capital V is perhaps the largest European fund dedicated to early-stage investing in life sciences and IT, with a focus on European companies.
BioPharmaceutical Medical Device

Serono Deals Its Way Into Oncology

It ought to be hard to convince an oncology-focused biotech to license its crown jewel to a firm without experience developing oncology drugs, but Serono SA was able to do just that-twice in the span of eight days-when it in-licensed Phase II and Phase III oncology programs, respectively, from Micromet AG and CancerVax Corp. in December.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Novuspharma SPA
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Italy
  • Parent & Subsidiaries
  • CTI BioPharma Corp.
  • Senior Management
  • Christina A Waters, PhD, Pres.
  • Contact Info
  • Cell Therapeutics Europe SRL
    Phone: (39) 2 61035 1
    Via Ariosto 23
    Bresso, 20091
    Italy
UsernamePublicRestriction

Register